Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221008598> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W4221008598 endingPage "1193" @default.
- W4221008598 startingPage "1186" @default.
- W4221008598 abstract "What is known and objective CC-292 is a potent, selective, orally administered small molecule inhibitor of bruton tyrosine kinase (BTK). The aim of this study was to evaluate the relative bioavailability of newly developed CC-292 tablet formulation (P22 tablet (P22-TAB) and CC-292 capsule formulation (P22 capsule [P22-CAP]) compared to the current CC-292 capsule formulation (P1 capsule [P01-CAP]). Methods This was an open-label, randomized, three-period, crossover study in healthy subjects (N = 12). Blood samples for pharmacokinetics (PK) assessment were collected up to 48 h postdose during each treatment period. Safety was evaluated throughout the study. Results and discussion For all three formulations, following administration of CC-292 at a dose level of 250 mg under fasted conditions, CC-292 was rapidly absorbed with maximum plasma concentrations (Cmax) occurring at a median of 1.5–1.75 h (Tmax). P22-CAP formulation showed a similar range of Tmax compared to P01-CAP and P22-TAB showed a wider range of Tmax compared to P01-CAP. Comparable or higher Cmax and AUC0-∞ were noted for P22-TAB and P22-CAP formulations as compared to P01-CAP formulation. The relative bioavailability (Frel) of the CC-292 P22-TAB compared to the P01-CAP reference formulation was 1.02, and the relative bioavailability (Frel) of the CC-292 P22-CAP compared to the P01-CAP reference formulation was 1.23. In conclusion, CC-292 was well tolerated when administered as single 250-mg oral doses of P22-TAB, P22-CAP or P01-CAP in the fasted state in this group of healthy subjects. Given that CC-292 has shown favourable safety profiles in the current clinical settings, the new formulations (P22-TAB and P22-CAP) are similar as the reference formulation (P01-CAP)." @default.
- W4221008598 created "2022-04-03" @default.
- W4221008598 creator A5028218508 @default.
- W4221008598 creator A5044095153 @default.
- W4221008598 creator A5045669688 @default.
- W4221008598 creator A5058075739 @default.
- W4221008598 creator A5075592850 @default.
- W4221008598 date "2022-03-20" @default.
- W4221008598 modified "2023-09-26" @default.
- W4221008598 title "An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase" @default.
- W4221008598 cites W1506889194 @default.
- W4221008598 cites W1982050984 @default.
- W4221008598 cites W2016455354 @default.
- W4221008598 cites W2033867789 @default.
- W4221008598 cites W2060041600 @default.
- W4221008598 cites W2106665711 @default.
- W4221008598 cites W2122695662 @default.
- W4221008598 cites W2134620914 @default.
- W4221008598 cites W2141111992 @default.
- W4221008598 cites W2153385611 @default.
- W4221008598 cites W2160367702 @default.
- W4221008598 cites W2346748817 @default.
- W4221008598 cites W2617432928 @default.
- W4221008598 cites W2983852549 @default.
- W4221008598 cites W3202213124 @default.
- W4221008598 doi "https://doi.org/10.1111/jcpt.13653" @default.
- W4221008598 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35307850" @default.
- W4221008598 hasPublicationYear "2022" @default.
- W4221008598 type Work @default.
- W4221008598 citedByCount "1" @default.
- W4221008598 countsByYear W42210085982023 @default.
- W4221008598 crossrefType "journal-article" @default.
- W4221008598 hasAuthorship W4221008598A5028218508 @default.
- W4221008598 hasAuthorship W4221008598A5044095153 @default.
- W4221008598 hasAuthorship W4221008598A5045669688 @default.
- W4221008598 hasAuthorship W4221008598A5058075739 @default.
- W4221008598 hasAuthorship W4221008598A5075592850 @default.
- W4221008598 hasBestOaLocation W42210085981 @default.
- W4221008598 hasConcept C112705442 @default.
- W4221008598 hasConcept C140793950 @default.
- W4221008598 hasConcept C142724271 @default.
- W4221008598 hasConcept C181389837 @default.
- W4221008598 hasConcept C185592680 @default.
- W4221008598 hasConcept C204787440 @default.
- W4221008598 hasConcept C22979827 @default.
- W4221008598 hasConcept C27081682 @default.
- W4221008598 hasConcept C2778778583 @default.
- W4221008598 hasConcept C42404028 @default.
- W4221008598 hasConcept C59822182 @default.
- W4221008598 hasConcept C71924100 @default.
- W4221008598 hasConcept C86803240 @default.
- W4221008598 hasConcept C87813604 @default.
- W4221008598 hasConcept C98274493 @default.
- W4221008598 hasConceptScore W4221008598C112705442 @default.
- W4221008598 hasConceptScore W4221008598C140793950 @default.
- W4221008598 hasConceptScore W4221008598C142724271 @default.
- W4221008598 hasConceptScore W4221008598C181389837 @default.
- W4221008598 hasConceptScore W4221008598C185592680 @default.
- W4221008598 hasConceptScore W4221008598C204787440 @default.
- W4221008598 hasConceptScore W4221008598C22979827 @default.
- W4221008598 hasConceptScore W4221008598C27081682 @default.
- W4221008598 hasConceptScore W4221008598C2778778583 @default.
- W4221008598 hasConceptScore W4221008598C42404028 @default.
- W4221008598 hasConceptScore W4221008598C59822182 @default.
- W4221008598 hasConceptScore W4221008598C71924100 @default.
- W4221008598 hasConceptScore W4221008598C86803240 @default.
- W4221008598 hasConceptScore W4221008598C87813604 @default.
- W4221008598 hasConceptScore W4221008598C98274493 @default.
- W4221008598 hasFunder F4320307115 @default.
- W4221008598 hasIssue "8" @default.
- W4221008598 hasLocation W42210085981 @default.
- W4221008598 hasLocation W42210085982 @default.
- W4221008598 hasOpenAccess W4221008598 @default.
- W4221008598 hasPrimaryLocation W42210085981 @default.
- W4221008598 hasRelatedWork W2349338867 @default.
- W4221008598 hasRelatedWork W2351830309 @default.
- W4221008598 hasRelatedWork W2356698425 @default.
- W4221008598 hasRelatedWork W2357220270 @default.
- W4221008598 hasRelatedWork W2374069256 @default.
- W4221008598 hasRelatedWork W2380630615 @default.
- W4221008598 hasRelatedWork W2392383498 @default.
- W4221008598 hasRelatedWork W2392867183 @default.
- W4221008598 hasRelatedWork W2401080248 @default.
- W4221008598 hasRelatedWork W48952282 @default.
- W4221008598 hasVolume "47" @default.
- W4221008598 isParatext "false" @default.
- W4221008598 isRetracted "false" @default.
- W4221008598 workType "article" @default.